With a profound commitment to a 'customer-first' approach, Greg’s vision for Recipharm is to be the leader in delivering high-quality solutions that drive customer success. Greg joined Recipharm from Nestlé Health Science (NHSc) where he was CEO and member of the Nestlé Executive Board. Prior to NHSc, Greg was CEO of Boehringer Ingelheim Pharmaceuticals US. He also led 14 countries globally, as well as the CV and Metabolism Franchise. His previous experience includes global management and market leadership roles at Novartis. Greg serves on the boards of Sonova AG and is Chairman of Amazentis SA, with past roles at Prometheus Biosciences (acquired by Merck) and Seres Therapeutics.